Integrative tumour mutation burden with CD39 and PD-L1 for the prediction of response to PD-L1 blockade and adjuvant chemotherapy in muscle-invasive bladder cancer patients

被引：0
|
作者：
Chunnan Liu
Zhaopei Liu
Kaifeng Jin
Han Zeng
Fei Shao
Yuan Chang
Yiwei Wang
Le Xu
Zewei Wang
Yu Zhu
Weijuan Zhang
机构：
[1] Fudan University Shanghai Cancer Center,Department of Urology
[2] Fudan University,Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences
[3] Fudan University,Department of Urology, Zhongshan Hospital
[4] Shanghai Jiao Tong University School of Medicine,Department of Oncology, Shanghai General Hospital
[5] Shanghai Jiao Tong University School of Medicine,Department of Urology, Shanghai Ninth People’s Hospital
[6] Shanghai Jiao Tong University School of Medicine,Department of Urology, Ruijin Hospital
[7] Fudan University,Department of Immunology, School of Basic Medical Sciences
来源：
British Journal of Cancer | 2022年 / 127卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1718 / 1725
页数：7
相关论文
共 50 条
  • [41] PD-1/PD-L1 blockade in cancer treatment: perspectives and issues
    Hamanishi, Junzo
    Mandai, Masaki
    Matsumura, Noriomi
    Abiko, Kaoru
    Baba, Tsukasa
    Konishi, Ikuo
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2016, 21 (03) : 462 - 473
  • [42] PD-1/PD-L1 blockade in cancer treatment: perspectives and issues
    Junzo Hamanishi
    Masaki Mandai
    Noriomi Matsumura
    Kaoru Abiko
    Tsukasa Baba
    Ikuo Konishi
    International Journal of Clinical Oncology, 2016, 21 : 462 - 473
  • [43] Prognostic importance of PD-L1 expression in bladder cancer patients
    Durur, Sumeyye
    Uzun, Hakki
    Bedir, Recep
    Nalkiran, Ihsan
    Nalkiran, Hatice Sevim
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2023, 19 (SUPPL 2) : S633 - S638
  • [44] Prognostic importance of PD-L1 expression in bladder cancer patients
    Durur, Sumeyye
    Uzun, Hakki
    Bedir, Recep
    Nalkiran, Ihsan
    Nalkiran, Hatice Sevim
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2023, 19 : S633 - S638
  • [45] PD-L1 Immunotherapy shrinks tumors in Bladder Cancer Patients
    不详
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2015, 11 (09) : 2120 - 2120
  • [46] Effect of cancer immunotherapy with CD39/PD-L1 bispecific antibody OriA631-b
    Li, Xiaopei
    Zhang, Yuchen
    Yang, Ze
    Deng, Qi
    Wang, Huajing
    Zhu, Haiyan
    Lu, Ligong
    Li, Xian-Yang
    Qu, Ryan
    He, Xiaowen
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [47] Safety of PD 1/PD-L1 Blockade in Patients with Hepatitis B Infection and Advanced Cancer
    Chen, H.
    He, F.
    Wu, K.
    Han, W. D.
    Feng, L. L.
    Pang, X. L.
    Liu, S.
    Zheng, J.
    Ma, Y.
    Lan, P.
    Huang, M. J.
    Zou, Y. F.
    Yang, Z. L.
    Wang, T.
    Fan, X.
    Wan, X.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2020, 108 (03): : E634 - E634
  • [48] PD-1/PD-L1 and DNA Damage Response in Cancer
    Kciuk, Mateusz
    Kolat, Damian
    Kaluzinska-Kolat, Zaneta
    Gawrysiak, Mateusz
    Drozda, Rafal
    Celik, Ismail
    Kontek, Renata
    CELLS, 2023, 12 (04)
  • [49] Assessment of PD-L1 Expression on Circulating Tumor Cells for Predicting Clinical Outcomes in Patients with Cancer Receiving PD-1/PD-L1 Blockade Therapies
    Tan, Zhaoli
    Yue, Chunyan
    Ji, Shoujian
    Zhao, Chuanhua
    Jia, Ru
    Zhang, Yun
    Liu, Rongrui
    Li, Da
    Yu, Qian
    Li, Ping
    Hu, Zhiyuan
    Yang, Yanlian
    Xu, Jianming
    ONCOLOGIST, 2021, : e2227 - e2238
  • [50] Comparison the results from PD-L1 IHC and PD-L1 multiplex immunofluorescence for the prediction of anti-PD-1 immunotherapeutic response
    Sun, Hongzhe
    Liu, Xia
    Jiao, Tao
    Guo, Qian
    Du, Haizhen
    Han, Shuo
    Zhu, Lin
    Zhang, Zhifu
    Kong, Yan
    Li, Na
    CANCER RESEARCH, 2024, 84 (06)
12345